SUPPLEMENTAL DATA

Supplemental Methods. Additional information on the methodology used in this manuscript.

Supplemental Figure 1. Glucose data

Supplemental Figure 2. Parasite KIR gene expression

Supplemental Figure 3. Differentially expressed genes with reductions in the post-SRx phase Supplemental Acknowledgments. List of members of the Malaria Host-Pathogen Interaction Center (MaHPIC)

Supplemental References

SUPPLEMENTAL METHODS

Rhesus macaque longitudinal infection

The longitudinal experiment included baseline collection of venous blood and bone marrow aspirates 5 days before sporozoite inoculation and daily follow-up for 100 days after the inoculation (about 100 freshly isolated salivary gland sporozoites were inoculated in the saphenous vein at day 0). Capillary blood samples were collected every day during the infection (approximately 100 µL), into EDTA-coated capillary tubes, using ear-prick procedures. Capillary blood samples were used for complete blood counts (CBCs) analysis using a Beckman Coulter AcTDiff hematology analyzer, to quantify parasitemias and stage differentials using Giemsa-stained thin and thick smears, to quantify reticulocytes by manual counting using new methylene blue staining of blood samples (10 mL) obtained from the femoral vein and bone marrow aspirates derived from iliac crest puncture while the animals were under anesthesia were

collected into EDTA-coated vacutainer tubes at seven TPs. For parasite transcriptomics, venous blood was collected in Blood Tempus RNA tubes containing 6 mL of Stabilizing Reagent, shaken vigorously for 10 seconds and stored at -80°C until processing for RNA-Seq. For metabolomics, a 300 µL aliquot of venous blood was centrifuged, and plasma was collected and stored at -80°C until processing for HRM.

To avoid possible clinical complications, subcurative treatment with artemether, a fastacting antimalarial drug with a short half-life, was administered intramuscularly (IM) at 1 mg/kg. This treatment was repeated when clinically warranted, and fluid support and blood transfusion were also treatment options if deemed necessary by veterinarians. Before unassignment, the macaques received a curative antimalarial regimen of 4 mg/kg of artemether IM followed by 2 mg/kg/day IM for seven days.

For bone marrow cytology, aspirate films were prepared immediately, fixed in methanol and stained with Wright-Giemsa. Total counts were determined using a Beckman Coulter AcTDiff hematology analyzer. Differential cell counts were performed by a board-certified veterinary pathologist using a blinded procedure and manual counting of 500 progenitor cells. To determine the absolute counts of erythroid and myeloid progenitor cells, they were summed for each TP and multiplied by the total nucleated cell count. This provided a cells/µL measure for both lineages. To summarize these data by phase, mean values were calculated per animal per phase.

Human sample collection

Venous blood samples were collected in heparin tubes by MVRU staff between August 2011 and August 2014. Giemsa-stained thick and thin blood smears were prepared for

parasitemia determination and species identification. PCR was additionally performed at the MVRU in Bangkok to confirm the parasite species.

Venous blood samples were also collected from the NMFI and healthy controls. Three mL was collected for a CBC test, parasite checks by microscopy, and PCR. One mL was collected in a heparin tube for plasma separation. All blood samples were kept on ice and transferred less than 4 hours later to the Tropical Disease Research Center in Kanchanaburi, or the MVRU in Bangkok. Plasma was separated by centrifugation, aliquoted and frozen at -80°C. A frozen aliquot of 200 μ L from each participant was shipped on dry ice to Emory University and remained frozen until used for HRM analysis. Samples were refrozen and thawed later for Biocrates targeted validation analyses.

Annotation of untargeted metabolomics data

Initial evaluation of metabolite features has been previously discussed (1) concerning metabolite identification, for example, multiple ions can be formed from a single metabolite, and one m/z feature may include ions from different chemicals. For simplicity, m/z features are discussed as metabolites; identities of metabolites have been established for this platform by tandem mass spectrometry (MS/MS), co-elution with authentic standards and cross-platform validation(1). Accurate mass matches (10 ppm) of other ions to metabolites were obtained using the xMSannotator package available Source R on Forge (<u>https://sourceforge.net/projects/xmsannotator/</u>) (2, 3). xMSannotator, which uses a multi-step procedure based on clustering based on intensities across samples, retention time, adducts/isotopes, mass defect, and correlation between adducts/isotopes was used to assign confidence levels (0: low/no confidence; 2: medium confidence; 3: high confidence) to database matches in HMDB. Metabolite identification levels are assigned according to the criteria established by the metabolomics standards initiative(4). Level 1 includes metabolites confirmed by matching accurate mass, retention time, and MS/MS relative to authentic standards. Level 2a includes metabolites confirmed by MS/MS relative to online spectral libraries. Level 2b includes computationally derived putative annotations using xMSannotator with annotation score 2 or 3, corresponding to medium to high confidence, respectively."

Targeted metabolite quantification

Targeted metabolite quantification was performed according to manufacturer instructions (Biocrates Life Sciences AG, Innsbruck, Austria). Samples were randomized into a 96-well plate for extraction. The methanolic extracts in the 96-well capture plate were split for data acquisition using two different approaches- LC-MS/MS in positive mode and flow injection analysis (FIA) in positive and negative mode. The LC-MS/MS approach uses column for metabolites separation in contrast to the FIA approach that does not utilize column. The data were acquired injecting 10 µl of extract into SCIEX LC AC chromatography system coupled to SCIEX QTRAP 5500 (AB SCIEX LLC, Framingham, MA, USA). The data acquired in multiple reaction monitor (MRM) mode were further processed and quantified using Analyst 1.6.3 and validated using MetIDQ software (Biocrates Life Sciences AG, Innsbruck, Austria).

Quality Control for Parasite Transcriptional Analysis

A set of quality control evaluations were conducted to ensure that the results of our parasite transcriptional analysis are reliable and meaningful. The results of these assessments and the steps taken to appropriately analyze this data are described below.

- <u>Negligible contribution of sequencing error to this dataset</u>. We aligned reads from TP1 (pre-inoculation, no *Plasmodium* in blood) with the *P. coatneyi* genome in order to test for non-specific alignment errors that would have created non-specific reads in our data set. The vast majority of the 5,578 annotated *P. coatneyi* genes had either 0 or 1 reads assigned in TP1. Genes found to have greater than 10 reads in any animal at TP1 were removed from analysis.
- 2. Expression levels for housekeeping genes were used to set the lower limit of detection for further analysis of parasite transcriptomes. As RNAseq and differential gene expression analysis has previously been shown to work reliably on populations of as little as 5,000 parasites with 100,000 reads (Ngara et al 2018), we decided to perform analysis on our dataset to determine whether we could reliably detect housekeeping markers in our samples that fell in the range of 100,000 parasite reads and greater. We identified putative housekeeping genes by identifying *P. coatneyi* orthologs of genes previously published shown to be constitutively expressed in *P. falciparum*. We then analyzed expression levels of such genes and found that in the samples with at least 100,000 parasite reads, the constitutively expressed genes could be reliably identified in all samples.
- 3. <u>A library size normalization was applied to account for differences in parasite read count</u> across the acute, post-treatment and chronic phases. After the samples were selected

(9 in total: 3 animals with one sample per phase, all of which met the quality control criteria), a library normalization was applied to all samples together using DESeq2.

4. <u>A base mean cutoff was used to eliminate those genes for which expression was very</u>

<u>low</u>. Following normalization, genes were only analyzed if they had a base mean normalized read count of greater than 4.

SUPPLEMENTAL TABLES

Table S1. Supplemental hematology data. Mean values per animal per phase for various hematological factors. Full dataset and metadata descriptions are available on the E03 clinical malaria data table on PlasmoDB.org (http://plasmodb.org/plasmo/mahpic.jsp).

Chronic	Chronic	Chronic	Chronic	Post- SubRx	Post- SubRx	Post- SubRx	Post- SubRx	Acute	Acute	Acute	Acute	Prepatent	Prepatent	Prepatent	Prepatent	phase
RWr13	RZe13	RUn13	RTi13	RWr13	RZe13	RUn13	RTi13	RWr13	RZe13	RUn13	RTi13	RWr13	RZe13	RUn13	RTi13	animal
152	131	165	141	2216	7280	7577	16960	35790	32510	47531	64511	0	0	0	0	parasites
13070	14695	16817	22978	10480	10092	10070	16240	9910	7329	8338	8971	13664	10213	10040	12767	WBC
4573279	5259250	5648000	5238889	3990667	4597632	5254048	4153333	5359000	6165714	6952500	5485714	6417857	6568667	7248462	5919333	RBC
11	12	12	12	10	10	11	10	13	14	15	13	15	15	16	14	hgb
40	41	42	45	34	36	39	35	42	47	51	43	53	52	55	49	hct
87	79	74	87	85	79	74	85	79	30	73	78	83	79	76	82	mcv
433364	309710	314971	373889	417467	305789	331152	378209	344000	203857	266038	254571	463214	329667	347420	361867	plt
16	15	16	17	20	18	18	20	13	14	16	14	14	15	17	15	rdw
8	8	8	9	8	8	8	9	8	8	8	9	9	9	8	10	ndu
38	20	17	17	39	27	30	31	43	27	37	35	38	21	30	30	gran
51	70	74	73	50	56	60	59	42	56	50	50	47	65	59	55	lymph
271049	168155	187800	97858	471410	285023	323070	319480	115465	63769	86546	122060	58809	73531	86052	71560	reticulocytes
4.16	2.62	2.71	1.98	5.93	3.42	3.99	4.13	1.91	1.27	2.29	1.97	1.90	2.20	3.18	1.61	RPI
0.83	0.30	0.24	0.24	1.44	0.54	0.54	0.61	1.31	0.53	0.83	0.78	0.87	0.35	0.57	0.57	G/L Ratio
-	-	-	_					_	-	_	_	_	_	_	_	

SUPPLEMENTAL FIGURES



Supplemental Figure 1. Glucose data. A. Glucose as measured by blood chemistry (i-STAT) and **B.** Sum of hexoses as measured by targeted metabolomics (Biocrates). Data reveal no significant differences across phases by ANOVA.



Supplemental Figure 2. KIR gene expression data. HCA plots of differentially expressed parasite genes of the KIR gene family with manual clustering along the x-axis (columns are grouped by clinical phase and are always in the same order of animals: RWr13, Run13, RTi13).



The Malaria Host-Pathogen Interaction Center (MaHPIC) consortium at the time of this study included the following members: all manuscript authors and Amy Kong, Dalia Arafat, Jessica A. Brady, Chris Ibegbu, Luis L. Fonseca, Luiz G. Gardinassi, Sanjeev Gumber, Juan B. Gutierrez, Jay C. Humphrey, Ebru Karpuzoglu, Nicolas Lackman, Tracey J. Lamb, Mustafa Nural, Mariko S. Peterson, Jan Pohl, Sarah Pruett, Celia Saney, Maren L. Smith, Mark P. Styczynski, JoAnn Sullivan, Rabin Tirouvanziam, Elizabeth D. Trippe, Eberhard O. Voit, Tyrone Williams, Zerotti L. Woods, Weiwei Yin, Yi Yan.

SUPPLEMENTAL REFERENCES

- 1. Go YM, Walker DI, Liang Y, Uppal K, Soltow QA, Tran V, et al. Reference Standardization for Mass Spectrometry and High-resolution Metabolomics Applications to Exposome Research. *Toxicol Sci.* 2015;148(2):531-43.
- 2. Uppal K, Salinas JL, Monteiro WM, Val F, Cordy RJ, Liu K, et al. Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in Plasmodium vivax malaria. *PLoS One.* 2017;12(8):e0182819.
- 3. Uppal K, Walker DI, and Jones DP. xMSannotator: An R Package for Network-Based Annotation of High-Resolution Metabolomics Data. *Anal Chem.* 2017;89(2):1063-7.
- 4. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics*. 2007;3(3):211-21.